Blocking the IL-6 signaling pathway with IL-6R antibody can inhibit CRS, thus the IL-6R antagonist Tocilizumab may be key to reducing the mortality of CRS of severe COVID-19 [96]. The gene discussed is IL6; the disease is congenital rubella syndrome.